ALX2004 + ALX2004 + ALX2004
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
NSCLC (Advanced Non-small Cell Lung Cancer)
Conditions
NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC, Colo-rectal Cancer, Head and Neck Cancer, Esophageal Squamous Cell Carcinoma (ESCC)
Trial Timeline
Aug 18, 2025 → Dec 1, 2027
NCT ID
NCT07085091About ALX2004 + ALX2004 + ALX2004
ALX2004 + ALX2004 + ALX2004 is a phase 1 stage product being developed by ALX Oncology for NSCLC (Advanced Non-small Cell Lung Cancer). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07085091. Target conditions include NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer).
What happened to similar drugs?
7 of 20 similar drugs in NSCLC (Advanced Non-small Cell Lung Cancer) were approved
Approved (7) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
6
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07085091 | Phase 1 | Recruiting |
Competing Products
20 competing products in NSCLC (Advanced Non-small Cell Lung Cancer)